+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Enfuvirtide for Injection Market - Global Forecast 2025-2030- Product Image
Enfuvirtide for Injection Market - Global Forecast 2025-2030- Product Image
Sale

Enfuvirtide for Injection Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6127842
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global Enfuvirtide injection market is rapidly evolving, driven by innovation in HIV therapeutics and shifting stakeholder prioritization across developed and emerging regions. Recognized for its distinct mechanism in combating HIV resistance, Enfuvirtide injection is influencing investment, regulatory, and clinical decision-making worldwide.

Market Snapshot of the Enfuvirtide Injection Sector

The Enfuvirtide injection market is experiencing steady growth, anchored by the rising need for advanced antiretroviral solutions to manage resistant HIV strains. Growth is supported by biologic advancements, demand for patient-centric care, and new regulatory trends. With an increasing focus on overcoming supply chain pressures and broadening patient access, manufacturers and healthcare systems are recalibrating investment and distribution strategies. The sector continues to draw innovation, collaborative partnerships, and product lifecycle initiatives, as key global markets—particularly the Americas, EMEA, and Asia-Pacific—see diverse adoption and reimbursement landscapes emerging.

Scope & Segmentation: Comprehensive Landscape for Enfuvirtide Injection

The scope of the Enfuvirtide injection market spans all critical operational dimensions:

  • Distribution Channel: Clinics (general, specialty), hospitals (private, public), and retail pharmacies (chain, independent).
  • Patient Category: Treatment experienced (mono-resistant, multi-drug resistant) and treatment naive.
  • Age Group: Adults (general adult, senior) and pediatric (adolescent, child, neonatal).
  • Therapy Line: Second, third, fourth, and fifth-line (and beyond) therapy roles.
  • Dosage Form: Prefilled syringes and vials (90 mg, 180 mg), offering selection based on clinical preference and preparation needs.
  • Administration Setting: Inpatient (general wards, intensive care units) and outpatient (ambulatory clinics, home care).
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including major markets such as UK, Germany, France, and emerging countries), Asia-Pacific (China, India, Japan, Australia, and others).
  • Key Companies: F. Hoffmann-La Roche Ltd., Trimeris, Inc., Cipla Limited, Dr. Reddy’s Laboratories Limited, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Mylan N.V., Intas Pharmaceuticals Limited, Aurobindo Pharma Limited, Hetero Laboratories Limited.

The primary keyword enfuvirtide injection is central to evaluating current market forces and guiding future strategies.

Key Takeaways for Senior Stakeholders

  • Enfuvirtide injection is shaping treatment paradigms by addressing persistent HIV resistance when conventional therapies fail.
  • Segmented approaches reveal nuanced adoption drivers among general and specialty clinics, hospitals, and pharmacies, underscoring the value of tailored distribution models.
  • Patient segmentation by experience, resistance level, and age enables more precise therapy alignment, improving outcomes and resource allocation.
  • Regional regulatory environments and evolving reimbursement mechanisms require localized market access strategies for optimal positioning.
  • Collaboration between originators and generic producers is expanding supply resilience and access in resource-constrained settings, with competition fostering formulation innovation.

Tariff Impact: U.S. Manufacturing and Procurement Shifts

The introduction of 2025 United States tariffs on peptide APIs and excipients directly spurred cost increases for Enfuvirtide injection manufacturing. Supply chain players responded by renegotiating supply contracts, refining sourcing, and investing in efficiency and process intensification. Distribution partners adjusted logistics and inventory management to maintain market supply, while manufacturers emphasized value-based pricing as a result of new operational pressures. These dynamics prompted more agile and collaborative relationships to preserve consistent patient access amid evolving trade conditions.

Methodology & Data Sources

This report leverages thorough primary and secondary research, including structured expert interviews and reviews of clinical, regulatory, and supply chain data. Robust triangulation methods validate every insight, and findings are benchmarked to industry standards. All proprietary data is managed in line with strict confidentiality and compliance practices.

Why This Report Matters

  • Enables strategic foresight for investment, commercialization, and partnership initiatives across complex global HIV therapy markets.
  • Equips stakeholders with actionable intelligence on market trends, supply resilience, and patient-focused innovations.
  • Integrates region-specific dynamics, segmentation insights, and evolving technological trends for well-informed, data-driven decisions.

Conclusion

Enfuvirtide injection continues to redefine the HIV therapy landscape through innovation, collaboration, and adaptive market positioning. Senior decision-makers can leverage this comprehensive analysis to optimize strategy and drive sustainable growth across the global antiretroviral ecosystem.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing competition from biosimilar enfuvirtide formulations driving price erosion and access improvements
5.2. Development of long-acting enfuvirtide delivery systems integrating sustained release for better patient adherence
5.3. Rising demand for home-based enfuvirtide injection platforms coupled with digital adherence monitoring tools
5.4. Real-world evidence studies highlighting efficacy and safety of enfuvirtide in treatment-experienced HIV populations
5.5. Regulatory milestones and patent expirations accelerating biosimilar enfuvirtide approvals in emerging markets
5.6. Pharmaceutical collaborations exploring nanoparticle or liposomal enfuvirtide formulations to reduce injection frequency
5.7. Cost-effectiveness analyses comparing enfuvirtide combination regimens with emerging long-acting antiretroviral therapies
5.8. Global supply chain resilience strategies addressing cold chain requirements for enfuvirtide distribution in resource-limited settings
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Enfuvirtide for Injection Market, by Distribution Channel
8.1. Introduction
8.2. Clinics
8.2.1. General Clinics
8.2.2. Specialty Clinics
8.3. Hospitals
8.3.1. Private Hospitals
8.3.2. Public Hospitals
8.4. Retail Pharmacies
8.4.1. Chain Pharmacies
8.4.2. Independent Pharmacies
9. Enfuvirtide for Injection Market, by Patient Category
9.1. Introduction
9.2. Treatment Experienced
9.2.1. Mono-Resistant
9.2.2. Multi-Drug Resistant
9.3. Treatment Naive
10. Enfuvirtide for Injection Market, by Age Group
10.1. Introduction
10.2. Adult
10.2.1. General Adult
10.2.2. Senior
10.3. Pediatric
10.3.1. Adolescent
10.3.2. Child
10.3.3. Neonatal
11. Enfuvirtide for Injection Market, by Therapy Line
11.1. Introduction
11.2. Later Line
11.2.1. Fifth Line and Beyond
11.2.2. Fourth Line
11.3. Second Line
11.4. Third Line
12. Enfuvirtide for Injection Market, by Dosage Form
12.1. Introduction
12.2. Prefilled Syringes
12.3. Vials
12.3.1. 180 Mg Vial
12.3.2. 90 Mg Vial
13. Enfuvirtide for Injection Market, by Administration Setting
13.1. Introduction
13.2. Inpatient
13.2.1. General Ward
13.2.2. Intensive Care Unit
13.3. Outpatient
13.3.1. Ambulatory Clinics
13.3.2. Home Care
14. Americas Enfuvirtide for Injection Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Enfuvirtide for Injection Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Enfuvirtide for Injection Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd.
17.3.2. Trimeris, Inc.
17.3.3. Cipla Limited
17.3.4. Dr. Reddy’s Laboratories Limited
17.3.5. Teva Pharmaceutical Industries Ltd.
17.3.6. Sandoz International GmbH
17.3.7. Mylan N.V.
17.3.8. Intas Pharmaceuticals Limited
17.3.9. Aurobindo Pharma Limited
17.3.10. Hetero Laboratories Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ENFUVIRTIDE FOR INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ENFUVIRTIDE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ENFUVIRTIDE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ENFUVIRTIDE FOR INJECTION MARKET: RESEARCHAI
FIGURE 28. ENFUVIRTIDE FOR INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 29. ENFUVIRTIDE FOR INJECTION MARKET: RESEARCHCONTACTS
FIGURE 30. ENFUVIRTIDE FOR INJECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ENFUVIRTIDE FOR INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MONO-RESISTANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MONO-RESISTANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MULTI-DRUG RESISTANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MULTI-DRUG RESISTANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT NAIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT NAIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GENERAL ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GENERAL ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SENIOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SENIOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CHILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY NEONATAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY NEONATAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY FIFTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY FIFTH LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY FOURTH LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY FOURTH LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY 180 MG VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY 180 MG VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY 90 MG VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY 90 MG VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AMBULATORY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AMBULATORY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 179. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 182. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 183. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 184. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 185. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 186. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 187. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 188. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 189. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2024 (USD MILLION)
TABLE 190. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2025-2030 (USD MILLION)
TABLE 191. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 192. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 193. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 194. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 195. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 196. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 197. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 198. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 199. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2018-2024 (USD MILLION)
TABLE 200. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2025-2030 (USD MILLION)
TABLE 201. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 204. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 205. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 206. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 207. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
TABLE 208. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2025-2030 (USD MILLION)
TABLE 209. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2018-2024 (USD MILLION)
TABLE 210. CANADA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2025-2030 (USD MILLION)
TABLE 211. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 214. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 215. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 216. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 217. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 218. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 219. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 220. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 221. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2024 (USD MILLION)
TABLE 222. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2025-2030 (USD MILLION)
TABLE 223. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 226. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 227. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 228. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 229. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 230. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 231. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2018-2024 (USD MILLION)
TABLE 232. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2025-2030 (USD MILLION)
TABLE 233. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 234. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 235. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 236. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 237. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 238. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 239. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
TABLE 240. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2025-2030 (USD MILLION)
TABLE 241. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2018-2024 (USD MILLION)
TABLE 242. MEXICO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2024 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2024 (USD MILLION)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2025-2030 (USD MILLION)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 321. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, 2018-2024 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Enfuvirtide for Injection market report include:
  • F. Hoffmann-La Roche Ltd.
  • Trimeris, Inc.
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Mylan N.V.
  • Intas Pharmaceuticals Limited
  • Aurobindo Pharma Limited
  • Hetero Laboratories Limited

Related Topics

Related Reports

Enfuvirtide (CAS 159519-65-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Enfuvirtide (CAS 159519-65-0) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Penpulimab Injection Market - Global Forecast 2025-2030 - Product Image

Penpulimab Injection Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Atosiban Acetate for Injection Market - Global Forecast 2025-2030 - Product Image

Atosiban Acetate for Injection Market - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Injection Pen Market Size, Share & Trends Analysis Report By Product (Disposable, Reusable), By Application (Osteoporosis, Diabetes, Anaphylaxis), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Injection Pen Market Size, Share & Trends Analysis Report By Product (Disposable, Reusable), By Application (Osteoporosis, Diabetes, Anaphylaxis), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 170 Pages
  • Global
From
Clindamycin Phosphate Injections - Global Strategic Business Report - Product Image

Clindamycin Phosphate Injections - Global Strategic Business Report

  • Report
  • 285 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.